1. Rescue fecal microbiota transplantation for antibiotic-associated diarrhea in critically ill patients
- Author
-
Zhou Yang, Xinfang Pan, Bin Deng, Heena Buch, Wei Chen, Dian Huang, Zhifeng Li, Junyu Pan, Lili Hu, Zhihang Hu, Xiangtao Wu, Yufeng Huo, Xiaoyin Zhang, Yong Bai, Bota Cui, Chen Shen, Xuwei He, Yi Shan, Faming Zhang, Liuhui Chang, Yafei Liu, and Min Dai
- Subjects
Male ,Abdominal pain ,medicine.medical_treatment ,Multidrug resistance ,Critical Care and Intensive Care Medicine ,law.invention ,Fecal microbiota transplantation ,0302 clinical medicine ,law ,Rescue therapy ,030212 general & internal medicine ,Child ,APACHE ,Aged, 80 and over ,lcsh:Medical emergencies. Critical care. Intensive care. First aid ,Enema ,Middle Aged ,Intensive care unit ,Anti-Bacterial Agents ,Diarrhea ,Treatment Outcome ,Child, Preschool ,030211 gastroenterology & hepatology ,Female ,medicine.symptom ,Antibiotic-associated diarrhea ,Adult ,medicine.medical_specialty ,China ,Adolescent ,Critical Illness ,Infections ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,Adverse effect ,Survival rate ,Aged ,Retrospective Studies ,business.industry ,Research ,Clostridium difficile ,lcsh:RC86-88.9 ,Hematochezia ,Critical care ,Dysbiosis ,business - Abstract
Background Antibiotic-associated diarrhea (AAD) is a risk factor for exacerbating the outcome of critically ill patients. Dysbiosis induced by the exposure to antibiotics reveals the potential therapeutic role of fecal microbiota transplantation (FMT) in these patients. Herein, we aimed to evaluate the safety and potential benefit of rescue FMT for AAD in critically ill patients. Methods A series of critically ill patients with AAD received rescue FMT from Chinese fmtBank, from September 2015 to February 2019. Adverse events (AEs) and rescue FMT success which focused on the improvement of abdominal symptoms and post-ICU survival rate during a minimum of 12 weeks follow-up were assessed. Results Twenty critically ill patients with AAD underwent rescue FMT, and 18 of them were included for analysis. The mean of Acute Physiology and Chronic Health Evaluation (APACHE) II scores at intensive care unit (ICU) admission was 21.7 ± 8.3 (range 11–37). Thirteen patients received FMT through nasojejunal tube, four through gastroscopy, and one through enema. Patients were treated with four (4.2 ± 2.1, range 2–9) types of antibiotics before and during the onset of AAD. 38.9% (7/18) of patients had FMT-related AEs during follow-up, including increased diarrhea frequency, abdominal pain, increased serum amylase, and fever. Eight deaths unrelated to FMT occurred during follow-up. One hundred percent (2/2) of abdominal pain, 86.7% (13/15) of diarrhea, 69.2% (9/13) of abdominal distention, and 50% (1/2) of hematochezia were improved after FMT. 44.4% (8/18) of patients recovered from abdominal symptoms without recurrence and survived for a minimum of 12 weeks after being discharged from ICU. Conclusion In this case series studying the use of FMT in critically ill patients with AAD, good clinical outcomes without infectious complications were observed. These findings could potentially encourage researchers to set up new clinical trials that will provide more insight into the potential benefit and safety of the procedure in the ICU. Trial registration ClinicalTrials.gov, Number NCT03895593. Registered 29 March 2019 (retrospectively registered).
- Published
- 2019
- Full Text
- View/download PDF